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pregnancies. Methods: A prospective cohort study compared obstetric outcomes between individuals with
twin pregnancies who did and did not have ﬁbroids. Patients were considered for inclusion if they underwent
ﬁrst-trimester ultrasonography examination, and went on to deliver at the Beijing Obstetrics and Gynecology
Hospital between September 1, 2012 and December 31, 2014. Participants were grouped based on the presence
or absence of ﬁbroids and baseline demographics, ﬁbroid characteristics, and obstetric outcomes were recorded
and compared between the two groups. Results: In total, 153 patients with twin pregnancies were recruited; 51
hadﬁbroids and 102 did not. Patients in theﬁbroid group demonstrated a highermaternal age (P b 0.001), higher
pre-pregnancy body mass index (P=0.01), and higher rate of assisted reproductive technology use (P=0.04).
The presence of ﬁbroids was not associatedwith any change in obstetric outcomes, and obstetric outcomeswere
unaffected by the number, size, location, and type of ﬁbroids (all P N 0.05). Conclusion: Fibroids were not a risk
factor for any adverse obstetric outcomes among patients with twin pregnancies.
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Uterine ﬁbroids are the most commonly recorded benign tumors
of the female reproductive system, affecting 20%–60% of women of
reproductive age [1,2]. However, the true prevalence of ﬁbroids is likely
much higher owing to most ﬁbroids being asymptomatic [3]. Fibroid
incidence increases with age, approaching 70%–80% by the time
individuals reach 50 years of age [4].
Fibroids are known to occur in 0.1%–10.7% of pregnant women and
this incidence increases as with women choose to delay pregnancy
until later in life [2,5–7]. Fibroids have been reported to be associated
with 10%–40%of prepartum complications in patientswho are pregnant
[6]. Fibroids have been associated with abdominal pain, spontaneous
abortion, changes in fetal position, placental abruption, premature
rupture of membranes, cesarean deliveries, postpartum hemorrhage,
preterm delivery, and low birth weight infants [3,6,8].
The incidence of twin pregnancies has increased in recent years
[9,10] and the rate of ﬁbroids in twin pregnancies has been estimated
to be 2.3% [11]. Although a large number of studies have investigated
the inﬂuence of uterine ﬁbroids on obstetric outcomes, few studies
have included twin pregnancies. Consequently, following a ﬁbroidet, Chaoyang District, Beijing,
85110.
gy and Obstetrics. Published by Elsdiagnosis in a patientwith a twin pregnancy, it is challenging for doctors
to provide patient-speciﬁc clinical advice and treatment. The aim of the
present study was to investigate whether obstetric outcomes of twin
pregnancies were affected by whether patients had been diagnosed
with ﬁbroids, and to evaluate any effect of different ﬁbroid characteris-
tics on obstetric outcomes in twin pregnancies. Furthermore, changes in
ﬁbroids during pregnancy were recorded.
2. Materials and methods
The present prospective cohort study enrolled patients aged
20–45 years who attended ﬁrst-trimester ultrasonography examination
for a twin gestation at the Beijing Obstetrics and Gynecology Hospital,
China, between September 1, 2012 and December 31, 2014. Patients
were included if they underwent both subsequent prenatal care and
delivery at the study institution within the study period. Patients were
excluded if they had a history of cesarean delivery, myomectomy,
or uterine septum resection, or had been diagnosed with uterine
malformation, uterine adenomyosis (uterine adenomyoma), cardiovas-
cular or cerebrovascular diseases, diabetes mellitus, renal insufﬁciency,
hematopoietic system diseases, or any other serious condition. Patients
with at least oneﬁbroidmeasuring above 1 cm in diameterwere includ-
ed in theﬁbroid group and all other participantswere included in a con-
trol group. Following the identiﬁcation of the number of participants
meeting the inclusion criteria, participants were excluded from theevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Flow of participants evaluated for obstetric outcomes.
Table 1
Demographic characteristics.a
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size of the control and experimental groups. The study protocol was ap-
proved by the Beijing Obstetrics and Gynecology Hospital Institutional
Ethics Committee, and written informed consent was obtained from
all participants.
Following enrollment, patient history and demographic data were
recorded. All patients underwent routine ultrasonography examination
at least three times during pregnancy (at 11–14 weeks, 22–24 weeks,
and 28–32 weeks of pregnancy), except in cases of spontaneous or
induced abortions; ultrasonography examinations were performed by
expert obstetric and gynecologic sonographers at the study institution,
and patients and their attending physicians were asked to report any
obstetric outcomes and adverse events. During ultrasonography
examinations, ﬁbroid characteristics, including size, number, location,
and type, were recorded and the 11–14-week measurements were
used as reference values.
Details of obstetric events and outcomes were also recorded,
including threatened spontaneous abortion (vaginal bleeding occurring
at b28 weeks of pregnancy), premature rupture of membranes,Fig. 2. Flow of participants undergoing ultrasonography examinations to evaluate ﬁbroid
characteristics.placental abruption, placenta previa, polyhydramnios (amniotic ﬂuid
volume N7 cm or amniotic ﬂuid index N20 cm), oligohydramnios
(amniotic ﬂuid volume b2 cm or amniotic ﬂuid index b5 cm), any
admission to a healthcare facility for abdominal pain, mode of delivery
(vaginal delivery/cesarean delivery), pregnancy outcome (spontane-
ous/induced abortion, premature delivery [delivery at 28–36+6 weeks
of pregnancy], or delivery at 37–42 weeks of pregnancy), estimated
blood loss (bleeding volume within 24 hours of delivery), postpartum
hemorrhage (estimated blood loss ≥1000 mL for cesarean deliveries or
≥500 mL for vaginal deliveries), postpartum blood transfusion,
puerperal fever (patient temperature ≥38 °C), and duration of hospital
admission. Further, neonatal outcomes including length and weight
at delivery, 1-, 5-, and 10-minute Apgar scores, and any congenital
anomalies were documented.Variable Fibroid
group
(n = 51)
Control group
(n = 102)
P value
Age, y 34.90 ± 4.17 31.29 ± 3.52 b0.001
Pre-pregnancy body mass indexb 22.77 ± 3.64 21.11 ± 2.51 0.005
Menstrual history
Duration of complete menstrual
cycle, d
30.59 ± 4.01 33.55 ± 16.90 0.460
Duration of menstrual period, d 5.73 ± 1.04 5.46 ± 1.22 0.221
Pregnancy history
Gravidity 1.73 ± 1.13 1.82 ± 1.01 0.368
Parity 0.20 ± 0.14 0.07 ± 0.29 0.273
No. of prenatal examinations attended 8.96 ± 2.40 9.03 ± 2.61 0.873
Method of conception 0.039
Natural conception 18 (35) 54 (53)
Conception using assisted reproductive
technology
33 (65) 48 (47)
Ethnicity 0.908
Han ethnicity 47 (92) 96 (94)
Non-Han ethnicity 4 (8) 6 (6)
Smoker 0 1 (1) N0.99
Drinker 1 (2) 0 0.333
a Values are given as mean ± SD or number (percentage), unless indicated otherwise.
b Calculated as weight in kilograms divided by the square of height in meters.
Table 2
Maternal outcomes.a
Maternal outcomes Fibroid group (n = 51) Control group
(n = 102)
Unadjusted RR (95%CI) Adjusted RRb (95%CI) P value
Threatened spontaneous abortionc 21 (41) 38 (37) 1.18 (0.59–2.34) 0.73 (0.33–1.62) 0.433
Premature rupture of membranes 9 (18) 21 (21) 0.83 (0.35–1.96) 0.71 (0.26–1.91) 0.499
Placental abruption 0 0 NA NA
Placenta previa 0 1 (1) 0.00 0.00 0.997
Polyhydramniosd 3 (6) 6 (6) 1.00 (0.24–4.17) 1.32 (0.28–6.32) 0.730
Oligohydramniose 3 (6) 1 (1) 6.31 (0.64–62.28) 6.93 (0.49–98.37) 0.153
Admission for abdominal pain 3 (6) 4 (4) 1.53 (0.33–7.12) 2.13 (0.38–11.87) 0.387
Cesarean delivery 47 (92) 93 (91) 1.14 (0.33–3.89) 1.15 (0.29–4.50) 0.843
Postpartum hemorrhagef 1 (2) 9 (9) 0.42 (0.09–2.03) 0.45 (0.08–2.66) 0.377
Postpartum blood transfusion 2 (4) 7 (7) 0.55 (1.11–2.77) 0.53 (0.09–3.20) 0.485
Puerperal feverg 8 (16) 21 (21) 0.72 (0.29–1.76) 0.59 (0.21–1.67) 0.317
Abbreviations: RR, relative risk; CI, conﬁdence interval; NA, not applicable.
a Values are given as number (percentage) unless indicated otherwise.
b The RR was adjusted for age, pre-pregnancy body mass index, and mode of conception.
c Vaginal bleeding occurring at b28 weeks of pregnancy.
d Amniotic ﬂuid volume N7 cm or amniotic ﬂuid index N20 cm.
e Amniotic ﬂuid volume b2 cm or amniotic ﬂuid index b5 cm.
f Estimated blood loss ≥1000 mL during cesarean deliveries or ≥500 mL during vaginal deliveries.
g Patient temperature ≥38 °C.
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6 weeks after delivery) and the ﬁnal patient follow-up visits took
place during December 2014.
Qualitative variables were expressed as frequency and percentage;
quantitative variables were expressed as mean ± SD. Qualitative
variables were compared using the Pearson χ2 test, continuity correc-
tion χ2 test, and the Fisher exact test. Quantitative variables were com-
pared using the Student t test, Mann–Whitney U test, analysis of
variance, and the paired Student t test. Multivariable logistic regression
analysis was used to adjust for potential confounding factors when ex-
amining associations between variables and obstetric outcomes. All
data were analyzed using SPSS version 17.0 (SPSS Inc, Chicago, IL,
USA) and P b 0.05 was considered statistically signiﬁcant.
3. Results
In total, 656 patients with twin gestations presented at the study
institution for ﬁrst-trimester ultrasonography examinations during the
study period; ﬁbroids were identiﬁed and 57 patients and 599 had no
ﬁbroids. There were six patients excluded from the ﬁbroid group (one
patient had a history of myomectomy, three had a history of chronic
hypertension, one had a history of diabetes mellitus, and one patientTable 3
Maternal and neonatal outcomes. a
Outcome Fibroid group Control group P value
No. of patients 51 102
Duration of hospital admission, d 5.69 ± 2.60 4.97 ± 1.59 0.108
Pregnancy outcome 0.757
Spontaneous or induced abortion 2 (4) 4 (4)
Premature delivery 18 (35) 30 (29)
Delivery at 37–42 wk 31 (61) 68 (67)
No. of neonates 95 190
Length at delivery, cm 46.68 ± 2.76 46.98 ± 2.60 0.454
Delivery weight, g 2508.37 ± 461.85 2587.16 ± 385.38 0.412
No. of neonates with 1-minute
Apgar score ≤7
1 (1) 0 0.336
No. of neonates with 5-minute
Apgar score ≤7
1 (1) 0 0.336
No. of neonates with 10-minute
Apgar score ≤7
1 (1) 0 0.336
Neonatal congenital anomalies 4 (4) 8 (4) N0.99
a Values are given as number, mean ± SD, or number (percentage), unless indicated
otherwise.had uterine malformation) and 48 patients excluded from the control
group (25 patients had previously undergone a cesarean delivery,
eight had a history of myomectomy, six had a history of chronic
hypertension, ﬁve had uterine adenomyosis, three patients had a
history of diabetes mellitus, and one patient had uterine malformation)
based on the inclusion criteria. Tomaintain a 2:1 ratio between the sizes
of the control group/experimental groups, data from 449 randomly
selected patients in the control groups were excluded; this resulted in
obstetric-outcome data being included from 51 patients in the ﬁbroid
group and 102 patients in the control group (Fig. 1). Data from 11–14-
week, 22–24-week, and 28–32-week ultrasonography ﬁbroid examina-
tions were available for 31 patients (Fig. 2).
Higher maternal age (P b 0.001), higher pre-pregnancy body mass
index (P= 0.01), and greater use of assisted reproductive technology
(P = 0.04) were recorded among patients in the ﬁbroid group. No
other signiﬁcant differences were observed between the two patient
groups (Table 1).
The multivariate logistic regression analysis controlled for age, pre-
pregnancy body mass index, and method of conception as confounding
variables, and found no associations between patients having ﬁbroids at
11–14-week ultrasonography and any of the maternal outcomes
included in the model (Table 2).
No differenceswere observed in the obstetric outcomes between the
two patient groups (Table 3).
Maternal and obstetric outcomes were also compared between
patients with ﬁbroids below 5 cm in diameter and patients with ﬁbroids
of at least 5 cm in diameter at study enrollment. No differences were re-
corded in any of the maternal and obstetric outcome measures
(Table 4). Additionally, no signiﬁcant differences in maternal and
obstetric outcomes were observed when patients within the ﬁbroid
group were subdivided based on ﬁbroid number (1 or ≥2) (Table 5),
location (fundus uteri, anterior wall, lateral wall, or posterior wall)
(Table 6), and type (intramural or subserosal) (Table 7).
When changes in ﬁbroid size across the three ultrasonography
examinations were analyzed, a signiﬁcant increase in ﬁbroid size was
observed not only between the 11–14-week and 22–24-week
examinations, but also the 11–14-week and the 28–32-week examina-
tionswhenonlyﬁbroids below5 cm in diameterwere considered. How-
ever, no signiﬁcant differences were observed when comparing the
22–24-week and 28–32 week evaluations among ﬁbroids below 5 cm
in diameter. Additionally, no signiﬁcant differenceswere recorded forﬁ-
broids of at least 5 cm in diameter and no signiﬁcant differences were
observed among all ﬁbroids (Table 8).
Table 4
Comparison of obstetric outcomes between patients with different ﬁbroid sizes at enrollment. a
Outcome Patients with ﬁbroids b5 cm in diameter Patients with ﬁbroids ≥5 cm in diameter P value
No. of patients 34 17
Threatened spontaneous abortion b 2 (6) 5 (29) 0.061
Premature rupture of membranes 6 (18) 3 (18) N0.99
Placental abruption 0 0
Placenta previa 0 0
Polyhydramnios c 2 (6) 1 (6) N0.99
Oligohydramnios d 0 3 (18) 0.058
Admission for abdominal pain 2 (6) 1 (6) N0.99
Cesarean delivery 32 (94) 15 (88) 0.854
Postpartum hemorrhage e 2 (6) 1 (6) N0.99
Postpartum blood transfusion 1 (3) 1 (6) N0.99
Puerperal fever f 3 (9) 5 (29) 0.134
Pregnancy outcome 0.119
Spontaneous or induced abortion 0 2 (12)
Premature delivery 12 (35) 6 (35)
Delivery at 37–42 wk 22 (65) 9 (53)
Duration of hospital admission, d 5.56 ± 2.87 5.94 ± 1.98 0.147
No. of neonates 66 29
Length at delivery, cm 46.59 ± 2.89 46.90 ± 2.50 0.741
Delivery weight, g 2506.29 ± 481.60 2513.10 ± 421.53 0.948
No. of neonates with 1-minute Apgar score ≤7 1 (2) 0 N0.99
No. of neonates with 5-minute Apgar score ≤7 1 (2) 0 N0.99
No. of neonates with 10-minute Apgar score ≤7 1 (2) 0 N0.99
Neonatal congenital anomalies 1 (2) 3 (10) 0.156
a Values are given as number, number (percentage), or mean ± SD, unless indicated otherwise.
b Vaginal bleeding occurring at b28 weeks of pregnancy.
c Amniotic ﬂuid volume N7 cm or amniotic ﬂuid index N20 cm.
d Amniotic ﬂuid volume b2 cm or amniotic ﬂuid index b5 cm.
e Estimated blood loss ≥1000 mL during cesarean deliveries or ≥500 mL during vaginal deliveries.
f Patient temperature ≥38 °C.
Table 5
Comparison of obstetric outcomes between patients with different numbers of ﬁbroids at
enrollment.a
Outcome Patients with
single ﬁbroid
Patients with
multiple ﬁbroids
P value
No. of patients 32 19
Threatened spontaneous
abortion b
4 (13) 3 (16) N0.99
Premature rupture of membranes 6 (19) 3 (16) N0.99
Placental abruption 0 0
Placenta previa 0 0
Polyhydramnios c 2 (6) 1 (5) N0.99
Oligohydramnios d 1 (3) 2 (11) 0.638
Admission for abdominal pain 3 (9) 0 0.447
Cesarean delivery 29 (91) 18 (95) N0.99
Postpartum hemorrhage e 0 3 (16) 0.089
Postpartum blood transfusion 0 2 (11) 0.134
Puerperal fever f 6 (19) 2 (11) 0.702
Pregnancy outcome 0.571
Spontaneous or induced
abortion
1 (3) 1 (5)
Premature delivery 13 (41) 5 (26)
Delivery at 37–42 wk 18 (56) 13 (68)
Duration of hospital admission, d 5.97 ± 3.19 5.21 ± 0.92 0.936
No. of neonates 60 35
Length at delivery, cm 46.70 ± 2.71 46.66 ± 2.87 0.947
Delivery weight, g 2503.83 ± 440.62 2516.14 ± 502.76 0.901
No. of neonates with 1-minute
Apgar score ≤7
0 1 (3) 0.368
No. of neonates with 5-minute
Apgar score ≤7
0 1 (3) 0.368
No. of neonates with 10-minute
Apgar score ≤7
0 1 (3) 0.368
Neonatal congenital anomalies 2 (3) 2 (6) 0.978
a Values are given as number, number (percentage), or mean ± SD, unless indicated
otherwise.
b Vaginal bleeding occurring at b28 weeks of pregnancy.
c Amniotic ﬂuid volume N7 cm or amniotic ﬂuid index N20 cm.
d Amniotic ﬂuid volume b2 cm or amniotic ﬂuid index b5 cm.
e Estimated blood loss ≥1000 mL during cesarean deliveries or ≥500 mL during vaginal
deliveries.
f Patient temperature ≥38 °C.
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In the present study, the presence of ﬁbroids did not affect obstetric
outcomes among patients who had twin pregnancies. The size, number,
location, and type of ﬁbroids were also not signiﬁcantly associated
with adverse obstetric outcomes in the study cohort. A signiﬁcant
increase in ﬁbroid size was observed not only between 11–14 weeks
and 22–24 weeks, but also between 11–14 weeks and 28–32 weeks of
pregnancy among ﬁbroids that were below 5 cm in diameter at
ﬁrst examination.
There are inconsistent data regarding the impact of ﬁbroids on
pregnancy and even less data regarding how ﬁbroids inﬂuence obstetric
outcomes in twin pregnancies speciﬁcally. In the ﬁrst study to examine
obstetric outcomes among patients with ﬁbroids and twin pregnancies,
Stout et al. [11] reported no increase in adverse obstetric outcomes, con-
sistent with the present study. The control-group sample size in this
studywas large, with 2323 patients who did not have ﬁbroids included.
However, there were only 67 patients with ﬁbroids enrolled and the
study was retrospective.
Different features of ﬁbroids could affect pregnancy outcomes in
various ways. Compared with anterior ﬁbroids, posterior ﬁbroids larger
than 3 cm in diameter have been demonstrated to be associated with
severe pelvic pain in the study of Deveer et al. [12]. A study conducted
by Lam et al. [13] reported that women with ﬁbroids affecting the
lower part of the uterus experienced greater blood loss, higher rates of
cesarean delivery, and higher rates of postpartum hemorrhage com-
pared with women who had ﬁbroids affecting the body of the uterus.
However, ﬁbroid type (intramural, subserosal/intramural, and
subserosal)was not associatedwith adverse obstetric outcomes. Fibroid
size has been associated with admissions for ﬁbroid pain, postpartum
hemorrhage, postpartum blood transfusions, and increased blood loss
during delivery [13,14]. Although Shavell et al. [14] considered that pre-
term delivery was signiﬁcantly more frequent among patients with ﬁ-
broids larger than 5 cm in diameter, other studies have not
demonstrated any relationship between ﬁbroid size and adverse obstet-
ric outcomes such as premature rupture of membranes, placental
Table 6
Comparison of obstetric outcomes based on ﬁbroid location. a
Obstetric outcomes Location of ﬁbroid(s) P value
Fundus uteri Anterior wall Lateral wall Posterior wall
No. of patients 5 28 5 13
Threatened spontaneous abortion b 2 (40) 3 (11) 0 2 (15) 0.266
Premature rupture of membranes 0 6 (21) 0 3 (23) 0.443
Placental abruption 0 0 0 0
Placenta previa 0 0 0 0
Polyhydramnios c 0 3 (11) 0 0 0.454
Oligohydramnios d 0 2 (7) 1 (20) 0 0.391
Admission for abdominal pain 1 (20) 0 0 2 (15) 0.112
Cesarean delivery 4 (80) 26 (93) 4 (80) 13 (100) 0.366
Postpartum hemorrhage e 0 2 (7) 0 1 (8) 0.854
Postpartum blood transfusion 0 1 (4) 0 1 (8) 0.824
Puerperal fever f 1 (20) 5 (18) 2 (40) 0 0.185
Pregnancy outcome 0.101
Spontaneous or induced abortion 1 (20) 0 1 (20) 0
Premature delivery 2 (40) 9 (32) 0 4 (31)
Delivery at 37–42 wk 2 (40) 19 (68) 4 (80) 9 (69)
Duration of hospital admission, d 6.40 ± 3.44 5.96 ± 3.06 5.40 ± 1.67 4.92 ± 1.04 0.610
No. of neonates 8 53 8 26
Length at delivery, cm 47.38 ± 1.51 46.26 ± 3.18 46.88 ± 1.13 47.27 ± 2.39 0.406
Delivery weight, g 2633.75 ± 219.02 2461.60 ± 504.96 2588.75 ± 210.30 2540.38 ± 482.80 0.689
No. of neonates with 1-minute Apgar score ≤7 0 1 (2) 0 0 0.849
No. of neonates with 5-minute Apgar score ≤7 0 1 (2) 0 0 0.849
No. of neonates with 10-minute Apgar score ≤7 0 1 (2) 0 0 0.849
Neonatal congenital anomalies 0 2 (4) 0 2 (8) 0.680
a Values are given as number, number (percentage), or mean ± SD, unless indicated otherwise.
b Vaginal bleeding occurring at b28 weeks of pregnancy.
c Amniotic ﬂuid volume N7 cm or amniotic ﬂuid index N20 cm.
d Amniotic ﬂuid volume b2 cm or amniotic ﬂuid index b5 cm.
e Estimated blood loss ≥1000 mL during cesarean deliveries or ≥500 mL during vaginal deliveries.
f Patient temperature ≥38 °C.
Table 7
Comparison of obstetric outcomes based on ﬁbroid type. a
Outcome Fibroid type P value
Intramural Subserosal
No. of patients 43 8
Threatened spontaneous
abortion b
6 (14) 1 (13) N0.99
Premature rupture of membranes 9 (21) 0 0.357
Placental abruption 0 0
Placenta previa 0 0
Polyhydramnios c 3 (7) 0 N0.99
Oligohydramnios d 3 (7) 0 N0.99
Admission for abdominal pain 2 (5) 1 (13) 0.407
Cesarean delivery 39 (91) 8 (100) N0.99
Postpartum hemorrhage e 3 (7) 0 N0.99
Postpartum blood transfusion 2 (5) 0 N0.99
Puerperal fever f 7 (16) 1 (13) N0.99
Pregnancy outcome 0.823
Spontaneous of induced
abortion
2 (5) 0
Premature delivery 15 (35) 3 (38)
Delivery at 37–42 wk 26 (60) 5 (63)
Duration of hospital admission, d 5.70 ± 2.58 5.63 ± 2.88 0.566
No. of neonates 79 16
Length at delivery, cm 46.80 ± 2.69 46.13 ± 3.10 0.595
Delivery weight, g 2530.19 ± 449.84 2400.63 ± 519.29 0.564
No. of neonates with 1-minute
Apgar score ≤7
0 1 (6) 0.168
No. of neonates with 5-minute
Apgar score ≤7
0 1 (6) 0.168
No. of neonates with 10-minute
Apgar score ≤7
0 1 (6) 0.168
Neonatal congenital anomalies 4 (5) 0 N0.99
a Values are given as number, number (percentage), or mean ± SD, unless indicated
otherwise.
b Vaginal bleeding occurring at b28 weeks of pregnancy.
c Amniotic ﬂuid volume N7 cm or amniotic ﬂuid index N20 cm.
d Amniotic ﬂuid volume b2 cm or amniotic ﬂuid index b5 cm.
e Estimated blood loss ≥1000 mL during cesarean deliveries or ≥500 mL during vaginal
deliveries.
f Patient temperature ≥38 °C.
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8,13,15,16].
The inﬂuence of the number of ﬁbroids on obstetric outcomes is still
controversial. Lam et al. [13] reported a higher preterm delivery rate
among patients with multiple ﬁbroids compared with those with a
singleﬁbroid. Similarly, Ciavattini et al. [15] observed increased preterm
delivery, cesarean-delivery, and breech presentation rates among
individuals with multiple ﬁbroids compared with single ﬁbroids or no
ﬁbroids. However, Qidwai et al. [2] recorded no correlation between
increasing numbers of ﬁbroids and adverse obstetric outcomes and
Lai et al. [16] reported no association between preterm delivery and
ﬁbroid number.
At present, the mechanisms through which ﬁbroids adversely affect
obstetric outcomes are still unknown. A hypothesized mechanism is
that ﬁbroids reduce the volume of the uterine cavity by physically
decreasing uteroplacental circulation and compressing vascular
structures, prompting inadequate placental growth that can lead to
some adverse obstetric outcomes [16]. Here it is hypothesized that
decreasing uterine distensibility, physical obstruction, contraction
patterns, inﬂammation, alterations to endometrial structures, and
molecular signaling could also be involved. Increased risk for adverse
obstetric outcomes could be related to global effects of ﬁbroids on the
uterus and placenta [8].
However, the present study failed to demonstrate any correlation
between adverse obstetric outcomes and the presence of ﬁbroids in
patients with twin pregnancies. One possible explanation for the
negative ﬁndings in the present study could be that twin pregnancies
resulted in reduced intrauterine space in comparison with singleton
pregnancies, making the narrowing of intrauterine space that occurs
as a result of ﬁbroids less signiﬁcant. Additionally, frequent prenatal
ultrasonography examinations could have helped to reduce the
occurrence of some adverse obstetric outcomes [11]; additionally, the
high rate of cesarean deliveries in patients with twin pregnancies
Table 8
Change of ﬁbroids during pregnancy (n = 31).a
Fibroids Fibroid diameter, cm P valueb P valuec P valued
Evaluated at 11–14 weeks
of pregnancy
Evaluated at 22–24 weeks
of pregnancy
Evaluated at 28–32 weeks
of pregnancy
All ﬁbroids 4.31 ± 1.87 4.48 ± 1.70 4.30 ± 1.58 0.428 0.287 0.981
Fibroids b5 cm in diameter at enrollment 2.87 ± 0.94 3.39 ± 1.36 3.45 ± 1.22 0.036 0.724 0.018
Fibroids ≥5 cm in diameter at enrollment 6.06 ± 1.02 5.81 ± 0.95 5.53 ± 1.35 0.526 0.116 0.154
a Values are given as mean ± SD unless indicated otherwise.
b Comparison between 11–14-week and 22–24-week evaluations.
c Comparison between 22–24-week and 28–32-week evaluations.
d Comparison between 11–14-week and 28–32-week evaluations.
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between the two groups.
Changes in ﬁbroids during pregnancy remain controversial. Benaglia
et al. [17] reported remarkable ﬁbroid growth during initial pregnancy
and described human chorionic gonadotropin as a signiﬁcant factor
that caused this. Lev-Toaff et al. [18] reported that, in response to
increased estrogen during the ﬁrst trimester, ﬁbroids either increased
in size or remained unchanged. During the second trimester, smaller
ﬁbroids (2–6 cm) increased in size or remained unchanged whereas
larger ﬁbroids (N6 cm) decreased in size, likely owing to the beginning
of estrogen receptor downregulation. Finally, during the third trimester,
ﬁbroids decreased in size or remained unchanged owing to estrogen-
receptor downregulation. However, Rosati et al. [19] reported that
69% of women who were pregnant and had a ﬁbroid experienced no
increase in ﬁbroid volume. Conversely, Laughlin et al. [20] recorded
a pregnancy-related reduction in ﬁbroid size. In the present study,
ﬁbroids smaller than 5 cmat initial evaluation increased in sizewhereas
ﬁbroids that were at least 5 cm demonstrated no change in size during
the second trimester, consistent, to some extent, with the ﬁndings
of Lev-Toaff et al. [18]. However, it is impossible to predict the growth
of ﬁbroids accurately owing to ﬁbroids responding differently to preg-
nancy in different individuals. Additionally, no studies have yet clariﬁed
the effects of several confounding factors on the growth of ﬁbroids
during pregnancy.
On the base of prior studies, the present study was designed as a
prospective study, strengthening the results. Furthermore, a wider
range of obstetric outcomes were considered in the present study in
comparisonwith previous studies. Further, thepresent study investigat-
ed not only obstetric outcomes of twin pregnancies in patients with or
without ﬁbroids, but also associations between ﬁbroid characteristics
and obstetric outcomes. Finally, changes in ﬁbroids during gestation
were investigated. There were also some limitations to the current
study; the sample sizes were small for both patient groups and social
factors could have resulted in a high cesarean delivery rate owing to
the population only including twin pregnancies. Moreover, none of
the patients included in the ﬁbroid group had submucosal ﬁbroids; pa-
tients with submucosal ﬁbroids tend to elect for hysteroscopic ﬁbroid
resection prior to pregnancy and this could have affected the results.
In comparison with singleton pregnancies, the inﬂuence of ﬁbroids
on obstetric outcomes is unclear in twin pregnancies [11]. However,
the potential that twin pregnancy itself could be a risk factor for adverse
obstetric outcomes compared with singleton pregnancy should not be
neglected. Further, some signiﬁcant growth was observed in smaller
ﬁbroids between the ﬁrst and third ultrasonographic evaluations; con-
sequently, when encountering a twin pregnancy complicated by uterine
ﬁbroids, close monitoring and management are necessary during the
prenatal, intrapartum, and postpartum periods to ensure that timely
care is delivered if adverse obstetric outcomes occur.
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